Med. Pro Praxi 2005; 2: 47-48

Pohled na otázky kardiovaskulárního rizika moderních nesteroidních antirevmatik

MUDr. David Suchý
Oddělení klinické farmakologie, FN Plzeň

Společnost Merck Sharp Dohme zahájila dne 30. září celosvětově stahování léčivých přípravků obsahujících rofekoxib z trhu. Hlavním důvodem bylo vyhodnocení dat mezinárodní, randomizované a placebem kontrolované studie APPROVE (Adenomatous Polyp Prevention on Vioxx), které poukazovalo na zvýšený výskyt kardiovaskulárních příhod (infarktu myokardu a cévní mozkové příhody) v aktivně léčené skupině ve srovnání s placebovou větví. Relativní riziko kardiovaskulárních příhod se překvapivě začalo zvyšovat až po 18 měsících léčby, zvýšení rizika v prvních 18 měsících nebylo prokázáno. Rofekoxib byl pro zvýšené kardiovaskulární riziko sledován již od roku 2002. Cílem článku je stručně shrnout základní relevantní fakta, související s kardiovaskulárním rizikem spojeným s léčbou moderními nesteroidními antirevmatiky

Keywords: Klíčová slova: rofekoxib, kardiovaskulární riziko, COX-2 preferenční léky.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Suchý D. Pohled na otázky kardiovaskulárního rizika moderních nesteroidních antirevmatik. Med. praxi. 2005;2(2):47-48.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000; 343: 1520-1528. Go to original source... Go to PubMed...
    2. Bombardier C, Laine L, Reicin A, et al. for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-1528. Go to original source... Go to PubMed...
    3. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial: Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-1255. Go to original source... Go to PubMed...
    4. White WB, Faich G, Whelton A, et al. Comparison of thrombotic events in patiens treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.Am J Cardiol 2002; 89: 425-430. Go to original source... Go to PubMed...
    5. Whelton A, Fort JG, Puma JA, et al. Seletive COX-2 inhibitors and cardiorenal function:a randomised, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patiens. Am J Ther 2001; 8: 85-95. Go to original source... Go to PubMed...
    6. White WB, Kent J, Tailor A, et al. Effect of celecoxib on ambulatory blood pressure in hypertensive patiens on ACE inhibitors. Hypertension 2002; 39: 929-934. Go to original source... Go to PubMed...
    7. Baigent C, Patrono C. Selective cyclooxygenase-2 inhibitors, aspirin and cardiovascular disease: a reapraissal. Arthritis Rheum 2003; 48: 12-20. Go to original source... Go to PubMed...
    8. Koxiby a riziko gastrointestinálních, kardiovaskulárních a kožních nežádoucích účinků. www.sukl.cz.
    9. Farkouh ME, Kirshner A, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and gastrointestinal Event Trial (TARGET), cardiovascular outcomes:randomised, controlled trial.
    10. Degner F, Lanes S, van Ryn J, Sigmund R. Pharmacological and clinical profile of meloxicam. In:Therapeutic role of selective COX-2 inhibitors. Vane JR, Motting RM, William Harwey Press, London 1991.
    11. Schonfeld P. Gastrointestinal safety profile of meloxicam: a metaanalysis of systematic rewiew of randomised controlled trials. Am J Med 1999; Vol. 107 (6A): 48-54. Go to original source... Go to PubMed...
    12. Singh G, et al. Meloxicam does not increase the risk of acute myocardial infarction, congestive heart failure, edema or hypertension compared to NSAIDs: results from a pooled analysis of 27,039 patients. EULAR 2001 Ann Eur Cong of Rheumatology, Praha, 13.-16. 6. 2001 Ann Rheum Dis 2001; 60 (Suppl 1): 151. Go to original source...
    13. Degner F, et al. Gastrointestinal (GI), cardiovascular, renal and hepatic toxicity of the selective COX-2 inhibitors meloxicam in a systematic review of 48 studies in 117,755 patients. William Harvey Res Conf, Progress in the Field of Selective COX-2 Inhibitors', Nice, 2001; 30. 9. - 2. 10. 2001: 30.
    14. Layton D, et al. Comparison of the incidence rates of thromboembolic events reported for patiens prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology 2003; 42: 1342-1353. Go to original source... Go to PubMed...
    15. Layton D, et al. Comparison of the incidence rates of thromboembolic events reported for patiens prescribed celecoxib and meloxicam in general practice in England usány prescription-event monitoring (PEM) data. Rheumatology 2003; 42: 1354-1364. Go to original source... Go to PubMed...
    16. Altman R, Luciardi HL, Muntaner J, Del Rio F, Bergman SG, et al. Efficacy assesment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation. The nonsteroidal antiinflammatory drugs in unstable angina treatment-2 (NUT-2) pilot study. Circulation 2002; 106: 191-195. Go to original source... Go to PubMed...
    17. Štolfa J. Kardiovaskulární účinky COX-2 selektivních inhibitorů-postavení meloxikamu. Int med pro praxi 2003; 7: 348-352.
    18. Guidance from use of cyclo-oxygenaze selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for rheumatoid arthritis.Technology Appraisal Guidance-No. 27. National Institute for Clinical excelence (NICE) August 2001.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.